Table 4.
Risk of prostate cancer-specific mortality by SLCO2B1 and SLCO1B3 SNP genotypes in a population-based prostate cancer cohort*
| SNP | Genotype | Prostate Cancer Death | HR (95% CI) ^ | ||
|---|---|---|---|---|---|
| No @ | Yes | ||||
| SLCO2B1 | rs12422149 | GG | 993 (95.6) | 46 (4.4) | 1.00 (referent) |
| GA + AA | 210 (92.5) | 17 (7.5) | 1.99 (1.11 – 3.55) | ||
| SLCO2B1 | rs949069 | GG | 811 (95.5) | 38 (4.5) | 1.00 (referent) |
| GA + AA | 397 (93.9) | 26 (6.2) | 1.39 (0.82 – 2.34) | ||
| SLCO2B1 | rs2712819 | AA | 777 (95.0) | 41 (5.0) | 1.00 (referent) |
| AG + GG | 431 (95.1) | 22 (4.9) | 1.02 (0.60 – 1.77) | ||
| SLCO2B1 | rs2851069 | CC | 452 (95.2) | 23 (4.8) | 1.00 (referent) |
| CT + TT | 752 (94.7) | 42 (5.3) | 1.21 (0.72 – 2.05) | ||
| SLCO2B1 | rs7947726 | GG | 999 (95.1) | 51 (4.9) | 1.00 (referent) |
| AG + AA | 204 (94.0) | 13 (6.0) | 0.75 (0.37 – 1.53) | ||
| SLCO1B3 | rs4149117 | GG | 885 (95.4) | 43 (4.6) | 1.00 (referent) |
| GT + TT | 326 (93.7) | 22 (6.3) | 1.76 (1.00 – 3.08) | ||
| SLCO1B3 | rs3829311 | GG | 812 (95.0) | 43 (5.0) | 1.00 (referent) |
| GA + AA | 396 (94.7) | 22 (5.3) | 1.28 (0.74 – 2.23) | ||
| SLCO1B3 | rs4762803 | CC | 958 (94.8) | 53 (5.2) | 1.00 (referent) |
| CG + GG | 251 (95.4) | 12 (4.6) | 1.16 (0.59 – 2.30) | ||
*
Variable number of cases due to failed genotyping
@
Includes 115 men who died of non-prostate cancer causes and who were censored at time of death
^
Adjusted for age, PSA at diagnosis, Gleason score, stage, primary treatment, BMI and smoking status